Gender Dysphoria Market Insight, Epidemiology and Market Forecast, 2017-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gender Dysphoria - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Gender Dysphoria - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of gender dysphoria in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The gender dysphoria market report provides analysis regarding current treatment practices, market share of the individual therapies, and historical, current, and forecasted gender dysphoria market size from 2017 to 2030, segmented by seven major markets.

The report also covers current gender dysphoria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Epidemiology:

The Gender Dysphoria epidemiology chapters provide insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Gender dysphoria epidemiology is segmented by the total prevalent gender dysphoria cases, the gender-specific prevalence of gender dysphoria, and comorbidities associated with gender dysphoria. In addition, the report includes a thorough analysis of all segments.

Two major comorbidities associated with gender dysphoria include suicidal ideation and substance abuse. Amongst the 7MM, patients for suicidal ideation were higher than those of substance abuse.

According to the publisher's, the total prevalent population of Gender Dysphoria in seven major markets was 37,241 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounted for the highest number of gender dysphoria cases.

Market Outlook:

The market size of Gender Dysphoria is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest market size. Among EU5 countries, UK, in 2017, had the largest market size with USD 19.87 million, while France had the smallest market size of USD 3.74 million.

Drugs Uptake:

This section focuses on the rate of uptake of therapies that comprise the current treatment landscape in the gender dysphoria market during the study period, 2017-2030. Currently, the mainstay treatment option in the GD treatment landscape is hormonal therapy (HT), which includes feminizing hormone therapies and masculinizing hormone therapies. Combination of antiandrogens (spironolactone), progestins, medroxyprogesterone acetate, GnRH agonists (long-acting gonadotropin-releasing hormone-suppresses testosterone), finasteride, and estrogen (17-beta-estradiol) are the primary revenue-generating components used in the management of transgender women (male to female) and testosterone formulations are employed in case of female to male transition. The analysis covers market uptake by drugs, patient uptake by therapies, and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size. All of these will help investigate factors important in market uptake and make financial and regulatory decisions.

The dynamics of the GD market are currently a consequence of existing therapies, including high-cost surgeries. It can be summarized that basic science and human research efforts will need to be accompanied by translational approaches, where effective novel management methods and strategies are effectively translated from research settings to clinical practice.

Key Topics Covered:

1 Key Insights

2 Executive Summary of Gender Dysphoria

3 SWOT Analysis for Gender Dysphoria

4 Gender Dysphoria Market Overview at a Glance

4.1 Market Share (%) Distribution of Gender Dysphoria in 2017

4.2 Market Share (%) Distribution of Gender Dysphoria in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Definitions

5.3 Etiology

5.4 Gender identity and Development of Gender Dysphoria

5.5 Pathophysiology

5.6 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Prevalent Population of Gender Dysphoria

6.3 Assumptions and Rationale- 7 MM

7 Country-wise epidemiology of Gender Dysphoria

7.1 The United States

7.1.1 Prevalence of Gender Dysphoria in the United States

7.1.2 Gender-specific Prevalence of Gender Dysphoria in the United States

7.1.3 Comorbidities Associated with Gender Dysphoria in the United States

7.2 Germany

7.3 France

7.4 Italy

7.5 Spain

7.6 United Kingdom

7.7 Japan

8 Treatment

8.1 Guidelines

World Professional Association for Transgender Health (WPATH) Guidelines

Endocrine Society Guidelines

8.2 Patient journey

8.3 Case Study Title: Transgender Care in the Primary Care Setting

8.4 Access to healthcare services, insurance coverage and its impact on Trans people

8.5 Discrimination, social stigma, and other social issues

9 Unmet Needs

10 Gender Dysphoria: Seven Major Market Analysis

10.1 Key Findings

10.2 Market Size of Gender Dysphoria in 7MM

11 Market Outlook by Country

11.1 Assumption and Rationale

12 Market Drivers

13 Market Barriers

14 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/13v5gs